Yezan Munther Haddadin - 01 Oct 2025 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Director
Issuer ticker: OTLK
Reported as of: 01 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Oct 2025, 19:20:43 UTC
Prior SEC filing: 03 Oct 2024
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/Lawrence A. Kenyon, Attorney-in-Fact

Key filing fact

Yezan Munther Haddadin filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 03 Oct 2025.

Key facts

This page summarizes Yezan Munther Haddadin's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Oct 2025, 19:20.

Change

Previous filing in this sequence was filed on 03 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001718004 Primary reporting owner

Haddadin Yezan Munther

Relationship: Director
Address: C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN
Signature: /s/Lawrence A. Kenyon, Attorney-in-Fact
Signature date: 03 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +286,734
Change %
Price: $0.000000
Shares after: 286,734
Date: 01 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 286,734
Exercise price: $1.04
Footnotes: F1

OTLK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +95,969
Change %
Price: $0.000000
Shares after: 95,969
Date: 03 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,969
Exercise price: $1.06
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Footnote F2

The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.